MULTIPLE MYELOMA

In a post hoc analysis of the DREAMM-2 trial, belantamab mafodotin achieved deep and durable responses with no notable alterations in its safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma who had received ≥7 prior therapies.

A novel BCMA and CD3 targeted bispecific T-cell engaging immunotherapy agent TNB-383B has demonstrated significant responses at higher dose levels and tolerability at all dose levels, including mild cases of cytokine release syndrome, according to initial results of a phase 1 trial presented during the 2020 American Society of Hematology Annual Meeting.

The ongoing phase 1/2 DREAMM-6 trial demonstrated clinical activity and a good safety profile with the combination of belantamab mafodotin, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

Ciltacabtagene autoleucel demonstrated a significant response rate and showed a manageable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

Enriching the CAR molecule bb2121 with the PI3K inhibitor bb007 improved response and extended duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Updated findings from the phase 1 CRB-401 trial of the chimeric antigen receptor T-cell therapy idecabtagene vicleucel showed a consistently favorable risk profile as well as durable, ongoing responses in heavily pretreated patients with multiple myeloma.

Treatment with selinexor, bortezomib, and dexamethasone demonstrated an increase in overall response rate and progression-free survival in patients with multiple myeloma and high cytogenetic risk despite a dosing schedule that utilized 40% less bortezomib and 25% less dexamethasone during the first 24 weeks of treatment.

A once-per-week selinexor, bortezomib, plus dexamethasone treatment strategy appeared effective and convenient as treatment of patients with multiple myeloma who received at least 1 to 3 prior lines of therapy.

Caitlin Costello, MD, discusses choosing the optimal first-line therapy for patients with multiple myeloma.

The partial clinical hold placed by the FDA on the phase 1 chimeric antigen receptor T-cell clinical trial, MELANI-01, has now been lifted.

Regulatory applications have been submitted to the FDA and European Medicines Agency seeking approval of a subcutaneous form of daratumumab in combination with pomalidomide and dexamethasone as treatment of patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.

Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.

In evaluating MYC rearrangement and its correlation with disease burden and prognostics in newly diagnosed multiple myeloma, a group of Mayo Clinic investigators found that the alteration is associated with high disease burden and independently prognosticates adverse outcomes in patients.

The phase 3 CASSIOPEIA study met its primary end point of progression-free survival with daratumumab maintenance in newly-diagnosed multiple myeloma eligible for autologous stem cell transplant.

Kenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.

During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.

In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.

During a Targeted Oncology Case Based Peer Perspective event, Alex Mejia-Garcia, MD, discussed the case of a 51-year-old male patient with stage II multiple myeloma.

The FDA granted a Priority Review designation to idecabtagene vicleucel as treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.

Noopur S. Raje, MD, discusses the results of the BOSTON trial of selinexor, bortezomib, and dexamethasone in patients with multiple myeloma.

The efficacy of ixazomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo was shown in the phase 3 TOURMALINE-MM2 trial for patients with newly diagnosed multiple myeloma who were not eligible for autologous stem cell transplant, according to a press release from Takeda.

Adding the anti-CD38 antibody, daratumumab, to the standard of care regimen of lenalidomide, bortezomib, and dexamethasone, improved depth of response, stringent complete response , and minimal residual disease negativity, in a subgroup of Black patients who had newly diagnosed multiple myeloma, according to findings presented at the eighth annual Society of Hematologic Oncology meeting.

CLR 131 induced a clinically meaningful objective response rate of 40% as treatment of patients with multiple myeloma who are triple class refractory in the phase 2 CLOVER-1 clinical trial.

The FDA granted Priority Review to Melphalan flufenamide in combination with dexamethasone for the treatment of adult patients with multiple myeloma that is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Siddhartha Ganguly, MD, reviewed the case of a 51-year-old man with standard-risk multiple myeloma.

During a virtual Case Based Peer Perspective event, Cristina Gasparetto, MD, discussed the case of a geriatric male diagnosed with stage II multiple myeloma.

The FDA granted approval to the combination of daratumumab plus carfilzomib and dexamethasone as treatment of adult patients with relapsed or refractory multiple myeloma who have received up to 3 prior lines of therapy.

As part of a virtual Case Based Peer Perspective event, Jesus G. Berdeja, MC, discussed the treatment options for stage II multilple myeloma, based on a case of a 71-year female patient.

C. Ola Landgren, MD, PhD, discusses the use of chimeric antigen receptor T cells and CAR natural killer cells in the multiple myeloma setting.

A new study has identified genomic factors that appear to correlate with a better risk profile and better progression-free survival among patients with multiple myeloma. The findings, though preliminary, could someday lead to better patient empowerment and stratification.